{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:54:31Z","timestamp":1788893671849,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.xcrm.2024.101521","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T14:31:48Z","timestamp":1713796308000},"page":"101521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia"],"prefix":"10.1016","volume":"5","author":[{"given":"Shady","family":"Adnan Awad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olli","family":"Dufva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Klievink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Karjalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Ianevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paavo","family":"Pietarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daehong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapnil","family":"Potdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kourosh","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tero","family":"Aittokallio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"Wennerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101521_bib1","series-title":"Chronic Myeloid Leukemia Hematologic Malignancies","first-page":"17","article-title":"The Biology and Pathogenesis of Chronic Myeloid Leukemia","author":"Chereda","year":"2016"},{"key":"10.1016\/j.xcrm.2024.101521_bib2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J.\u00a0Clin. Orthod."},{"key":"10.1016\/j.xcrm.2024.101521_bib3","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Sau\u00dfele","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101521_bib4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3389\/fonc.2019.00939","article-title":"BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia","volume":"9","author":"Loscocco","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2024.101521_bib5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.hoc.2011.09.004","article-title":"Chronic Myeloid Leukemia\u00a0\u2013 Mechanisms of Resistance and Treatment","volume":"25","author":"Jabbour","year":"2011","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.xcrm.2024.101521_bib6","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101521_bib7","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2024.101521_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/leu.2016.154","article-title":"Effect of tyrosine kinase inhibitors on stemness in normal and chronic myeloid leukemia cells","volume":"31","author":"Charaf","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101521_bib9","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","article-title":"Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML","volume":"129","author":"Warfvinge","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101521_bib10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia","volume":"12","author":"Malani","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101521_bib11","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","article-title":"Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders","volume":"12","author":"Kornauth","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101521_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2022.09.001","article-title":"Ex\u00a0Vivo Expansion of Phenotypic and Transcriptomic Chronic Myeloid Leukemia Stem Cells","volume":"115","author":"Patel","year":"2022","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.xcrm.2024.101521_bib13","doi-asserted-by":"crossref","first-page":"22606","DOI":"10.18632\/oncotarget.15146","article-title":"Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors","volume":"8","author":"Pietarinen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2024.101521_bib14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2024.101521_bib15","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/bloodadvances.2020001934","article-title":"Ex\u00a0vivo drug screening defines novel drug sensitivity patterns for informing personalized therapy in myeloid neoplasms","volume":"4","author":"Spinner","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2024.101521_bib16","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","article-title":"Prioritization of cancer therapeutic targets using CRISPR\u2013Cas9 screens","volume":"568","author":"Behan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101521_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.canlet.2021.04.006","article-title":"Genome wide CRISPR screening reveals a role for sialylation in the tumorigenesis and chemoresistance of acute myeloid leukemia cells","volume":"510","author":"Lee","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.xcrm.2024.101521_bib18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019002121","article-title":"Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity","volume":"135","author":"Dufva","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101521_bib19","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.1002\/cam4.3231","article-title":"A genome-scale CRISPR knock-out screen in chronic myeloid leukemia identifies novel drug resistance mechanisms along with intrinsic apoptosis and MAPK signaling","volume":"9","author":"Lewis","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.xcrm.2024.101521_bib20","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101521_bib21","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","article-title":"Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia","volume":"123","author":"Herrmann","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101521_bib22","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/s41375-019-0684-5","article-title":"CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy","volume":"34","author":"Kinstrie","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101521_bib23","doi-asserted-by":"crossref","first-page":"W739","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2024.101521_bib24","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1021\/acs.jproteome.9b00028","article-title":"Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival","volume":"18","author":"Noel","year":"2019","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.xcrm.2024.101521_bib25","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","article-title":"Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia","volume":"4","author":"Adnan Awad","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2024.101521_bib26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.semcancer.2019.09.021","article-title":"Repurposing quinacrine for treatment-refractory cancer","volume":"68","author":"Oien","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.xcrm.2024.101521_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101425","article-title":"Low doses of niclosamide and quinacrine combination yields synergistic effect in melanoma via activating autophagy-mediated p53-dependent apoptosis","volume":"21","author":"Zheng","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.xcrm.2024.101521_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-Myc selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101521_bib29","article-title":"Multi cell line analysis of lysosomal proteomes reveals unique features and novel lysosomal proteins","author":"Akter","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.xcrm.2024.101521_bib30","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/15548627.2016.1256934","article-title":"Autolysosome biogenesis and developmental senescence are regulated by both Spns1 and v-ATPase","volume":"13","author":"Sasaki","year":"2017","journal-title":"Autophagy"},{"key":"10.1016\/j.xcrm.2024.101521_bib31","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.leukres.2017.10.012","article-title":"Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in\u00a0vivo effects","volume":"63","author":"Eriksson","year":"2017","journal-title":"Leuk. Res."},{"key":"10.1016\/j.xcrm.2024.101521_bib32","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1038\/s41467-021-27300-w","article-title":"Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia","volume":"12","author":"Wu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101521_bib33","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1180","article-title":"Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells","volume":"8","author":"Carter","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101521_bib34","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3324\/haematol.2019.219261","article-title":"Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem\/progenitor cells in a murine model","volume":"105","author":"Carter","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2024.101521_bib35","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1158\/1541-7786.MCR-18-1243","article-title":"Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer","volume":"17","author":"Stover","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101521_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110261","article-title":"WEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity","volume":"38","author":"Elb\u00e6k","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2024.101521_bib37","doi-asserted-by":"crossref","first-page":"9930","DOI":"10.1038\/s41598-020-66018-5","article-title":"Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer","volume":"10","author":"Ha","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2024.101521_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.leukres.2017.11.004","article-title":"Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine","volume":"64","author":"Garcia","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.xcrm.2024.101521_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.901132","article-title":"Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors","volume":"12","author":"Mancini","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.xcrm.2024.101521_bib40","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1038\/bcj.2015.30","article-title":"Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing","volume":"5","author":"Pietarinen","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.xcrm.2024.101521_bib41","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature14119","article-title":"Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation","volume":"519","author":"Pemovska","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101521_bib42","doi-asserted-by":"crossref","first-page":"5806","DOI":"10.1158\/0008-5472.CAN-21-1784","article-title":"Are CRISPR Screens Providing the Next Generation of Therapeutic Targets?","volume":"81","author":"Vazquez","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101521_bib43","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.3390\/cancers14153612","article-title":"High-Throughput CRISPR Screening in Hematological Neoplasms","volume":"14","author":"Ancos-Pintado","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2024.101521_bib44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","article-title":"Genome-scale CRISPR-Cas9 knockout screening in human cells","volume":"343","author":"Shalem","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101521_bib45","doi-asserted-by":"crossref","DOI":"10.1093\/g3journal\/jkaa069","article-title":"Identification of pathways modulating vemurafenib resistance in melanoma cells via a genome-wide CRISPR\/Cas9 screen","volume":"11","author":"Goh","year":"2021","journal-title":"G3 (Bethesda)."},{"key":"10.1016\/j.xcrm.2024.101521_bib46","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1126\/science.aac7041","article-title":"Identification and characterization of essential genes in the human genome","volume":"350","author":"Wang","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101521_bib47","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood-2022-165758","article-title":"A Single-Cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia","volume":"140","author":"Krishnan","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101521_bib48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/bloodadvances.2020002842","article-title":"KAT2A complexes ATAC and SAGA play unique roles in cell maintenance and identity in hematopoiesis and leukemia","volume":"6","author":"Arede","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2024.101521_bib49","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/2643-3230.BCD-21-0220","article-title":"Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1-Mutant Myelodysplastic Syndromes With Ringed Sideroblasts","volume":"3","author":"Adema","year":"2022","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101521_bib50","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020104862","article-title":"LRRK2 and Rab10 coordinate macropinocytosis to mediate immunological responses in phagocytes","volume":"39","author":"Liu","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.xcrm.2024.101521_bib51","doi-asserted-by":"crossref","first-page":"26434","DOI":"10.18632\/oncotarget.15507","article-title":"RAB10 overexpression promotes tumor growth and indicates poor prognosis of hepatocellular carcinoma","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.xcrm.2024.101521_bib52","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/j.1582-4934.2009.00795.x","article-title":"Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells","volume":"14","author":"Shi","year":"2010","journal-title":"J.\u00a0Cell Mol. Med."},{"key":"10.1016\/j.xcrm.2024.101521_bib53","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2020009676","article-title":"YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner","volume":"138","author":"Feng","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101521_bib54","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1182\/bloodadvances.2022009648","article-title":"YBX1 as an oncogenic factor in T-cell acute lymphoblastic leukemia","volume":"7","author":"Li","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.xcrm.2024.101521_bib55","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41467-020-20259-0","article-title":"Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem\/progenitor cells in chronic myelogenous leukemia","volume":"12","author":"Lei","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101521_bib56","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1038\/onc.2013.259","article-title":"Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer","volume":"33","author":"Panupinthu","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2024.101521_bib57","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/cns.13156","article-title":"KCTD: A new gene family involved in neurodevelopmental and neuropsychiatric disorders","volume":"25","author":"Teng","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.xcrm.2024.101521_bib58","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","article-title":"Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation","volume":"79","author":"Burslem","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101521_bib59","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature22376","article-title":"Genetic wiring maps of single-cell protein states reveal an off-switch for GPCR signalling","volume":"546","author":"Brockmann","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101521_bib60","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1038\/leu.2014.249","article-title":"AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells","volume":"28","author":"Nieborowska-Skorska","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101521_bib61","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.50223","article-title":"Genome-wide CRISPR screening reveals genetic modifiers of mutant EGFR dependence in human NSCLC","volume":"8","author":"Zeng","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.xcrm.2024.101521_bib62","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.3324\/haematol.2017.179937","article-title":"De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways","volume":"104","author":"Magistroni","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2024.101521_bib63","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41419-021-03732-6","article-title":"Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis","volume":"12","author":"Jiang","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.xcrm.2024.101521_bib64","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","article-title":"Breeze: an integrated quality control and data analysis application for high-throughput drug screening","volume":"36","author":"Potdar","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101521_bib65","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2024.101521_bib66","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","article-title":"MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens","volume":"15","author":"Li","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2024.101521_bib67","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1093\/nar\/gku936","article-title":"Easy quantitative assessment of genome editing by sequence trace decomposition","volume":"42","author":"Brinkman","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2024.101521_bib68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101521_bib69","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkt214","article-title":"The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote","volume":"41","author":"Liao","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2024.101521_bib70","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xcrm.2024.101521_bib71","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101521_bib72","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2024.101521_bib73","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2105-14-128","article-title":"Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.xcrm.2024.101521_bib74","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.xcrm.2024.101521_bib75","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101521_bib76","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101521_bib77","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41375-020-01011-5","article-title":"RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses","volume":"35","author":"Adnan Awad","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101521_bib78","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s42256-019-0122-4","article-title":"Prediction of drug combination effects with a minimal set of experiments","volume":"1","author":"Ianevski","year":"2019","journal-title":"Nat. Mach. Intell."},{"key":"10.1016\/j.xcrm.2024.101521_bib79","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanm\u00e4ki","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2024.101521_bib80","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41375-020-01082-4","article-title":"Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets","volume":"35","author":"Adnan-Awad","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.xcrm.2024.101521_bib81","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2010-11-3-r25","article-title":"A scaling normalization method for differential expression analysis of RNA-seq data","volume":"11","author":"Robinson","year":"2010","journal-title":"Genome Biol."},{"key":"10.1016\/j.xcrm.2024.101521_bib82","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/1467-9868.00346","article-title":"A Direct Approach to False Discovery Rates","volume":"64","author":"Storey","year":"2002","journal-title":"J.\u00a0Roy. Stat. Soc. B"},{"key":"10.1016\/j.xcrm.2024.101521_bib83","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1038\/s41467-020-16115-w","article-title":"Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124001903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124001903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T20:16:15Z","timestamp":1733775375000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124001903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2666379124001903"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101521","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101521"}}